
Opinion|Videos|March 28, 2025
Patient Burden Associated With Uncomplicated UTIs
Panelists discuss how patients with recurrent urinary tract infections (UTIs) describe significant burdens including constant anxiety about symptom onset, disruption to work and social life, financial strain from frequent office visits and medications, frustration with treatment-resistant infections, embarrassment discussing symptoms, sexual dysfunction, relationship difficulties, and substantial mental health impacts such as depression and diminished quality of life.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do patients with recurrent UTIs describe the burden of their condition, particularly in relation to treatment resistance, the frequency of office visits, and the impact on their daily lives and mental well-being?
Advertisement
Related to this article

Naim Alkhouri, MD, on when to judge MASH treatment response, counseling on weight and muscle loss, primary care screening, and future trial end points.

Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.

Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.

Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.

The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).

October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
Advertisement
Advertisement
Trending on AJMC
1
NYC Marathon Death Puts Rhabdomyolysis Risk Factors in Focus
2
Real-World Evidence, Rare Liver Disease Data Headline Kidney Week 2026
3
Disease Extent Linked to Complications After Deep Endometriosis Surgery
4
Cranberry Supplement Tied to Greater OAB Score Reductions in Pilot Trial
5


